{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:41:16Z","timestamp":1777318876153,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"name":"Novartis Pharma GmbH, Nuernberg, Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.1093\/ndt\/gfx075","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T19:13:10Z","timestamp":1491851590000},"page":"1060-1070","source":"Crossref","is-referenced-by-count":33,"title":["Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial"],"prefix":"10.1093","volume":"32","author":[{"given":"Klemens","family":"Budde","sequence":"first","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Zeier","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Department of Nephrology, University Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Arns","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, Cologne Merheim Medical Centre, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Guba","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, Munich University Hospital, Campus Grosshadern, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Jacobi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Kliem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Nephrology, Kidney Transplant Centre, Nephrological Centre of Lower Saxony, Klinikum Hann. M\u00fcnden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Intensive Care, Charit\u00e9 Campus Virchow, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Stahl","sequence":"additional","affiliation":[{"name":"III. Medical Clinic, University Hospital Hamburg, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rath","sequence":"additional","affiliation":[{"name":"University Hospital Westpfalz, Kaiserslautern, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Duerr","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Paulus","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuernberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"May","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuernberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Porstner","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuernberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the HERAKLES Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,10]]},"reference":[{"key":"key\n\t\t\t\t20180328181453_gfx075-B1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(98)80172-6","article-title":"Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling","volume":"10","author":"Abraham","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-2277.2010.01051.x","article-title":"mTOR inhibition: the learning curve in kidney transplantation","volume":"23","author":"Weir","year":"2010","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B3","first-page":"133","article-title":"mTOR inhibitor\/proliferation signal inhibitors: entering or leaving the field?","volume":"23","author":"Rostaing","year":"2010","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B4","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B5","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2013renal transplantation","volume":"21 (Suppl 3)","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"2","author":"Holdaas","year":"2011","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based regimen calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B9","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.transproceed.2009.08.065","article-title":"Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination","volume":"41","author":"Cataneo-D\u00e0vila","year":"2009","journal-title":"Transplant Proc"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transplant Int"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B11","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/TP.0b013e3181821c25","article-title":"Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus","volume":"86","author":"Morales","year":"2008","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B13","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/01.TP.0000063703.32564.3B","article-title":"A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization and elimination at six months in de novo renal allograft recipients","volume":"75","author":"Baboolal","year":"2003","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3\u2009months after renal transplantation: CONCEPT study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B16","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1681\/ASN.2005060635","article-title":"Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients","volume":"16","author":"Stallone","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study","volume":"83","author":"Budde","year":"2015","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B21","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24\u2009months in renal transplantation","volume":"95","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B23","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","article-title":"Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study","volume":"99","author":"Fischer","year":"2015","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trre.2005.10.005","article-title":"Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions","volume":"20","author":"Pascual","year":"2006","journal-title":"Transplant Rev"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00007890-200109150-00007","article-title":"Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure","volume":"72","author":"Johnson","year":"2001","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B31","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11255-014-0783-1","article-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis","volume":"46","author":"Su","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.trre.2015.09.001","article-title":"Everolimus immunosuppression in kidney transplantation: what is the optimal strategy?","volume":"30","author":"Witzke","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1517\/14656566.2012.662955","article-title":"Everolimus: preventing organ rejection in adult kidney transplant recipients","volume":"13","author":"Dantal","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/TP.0000000000000225","article-title":"Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients","volume":"99","author":"Oh","year":"2015","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/TP.0b013e3182421604","article-title":"Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction","volume":"93","author":"Piao","year":"2012","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B37","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B38","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation","volume":"28","author":"Mj\u00f6rnstedt","year":"2015","journal-title":"Transplant Int"},{"key":"key\n\t\t\t\t20180328181453_gfx075-B40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/32\/6\/1060\/17701466\/gfx075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T07:38:30Z","timestamp":1522309110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/6\/1060\/3866771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,10]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx075","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,6,1]]}}}